Oncology Corporate Profile
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics, which, in comparison with current alternatives, show improved properties, reduced side effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|paclical||mitotic inhibitor||Ovarian cancer||III|
|docecal||mitotic inhibitor||Breast cancer||II|
|paclical||mitotic inhibitor||Brain cancer||I|
|doxophys||anthracycline antibiotic||Breast cancer||Preclinical|
View additional information on product candidates here »